2026-01-21 - Analysis Report
**Company Overview**
Novo Nordisk is a Danish multinational pharmaceutical company focusing on discovery, development, production, and worldwide marketing of human disease treatments and pharmaceutical products.

**Return Rate Comparison**
- Return rate of the review stock (NVO): 49.25%
- Return rate of the comparison stock (VOO): 89.37%
- Divergence: -40.00 (-40.00% cumulative return difference)

**Alpha, Beta analysis**
|    | CAGR  | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018 | 0.0% | 19.0% | -5.0% | 0.8 | 102.4B |
| 2017-2019 | 37.0% | 13.6% | 20.0% | 0.6 | 128.6B |
| 2018-2020 | 1.0% | 12.5% | -20.0% | 0.6 | 155.2B |
| 2019-2021 | 58.0% | 13.0% | 15.0% | 0.6 | 248.8B |
| 2020-2022 | 58.0% | 23.2% | 60.0% | 0.6 | 300.7B |
| 2021-2023 | 87.0% | 23.2% | 86.0% | 0.5 | 459.7B |
| 2022-2024 | 18.0% | 40.5% | -1.0% | 0.5 | 382.2B |
| 2023-2025 | -52.0% | 59.7% | -114.0% | 0.7 | 226.1B |

**Stock Price Fluctuations**
- 5-day SMA: $59.74
- 20-day SMA: $55.07
- 60-day SMA: $50.85
- Recent Price change: -$2.65 (from $62.33 to $60.68)

**RSI, PPO Index Indicators, Delta_Previous_Relative_Divergence, Expected_Return**
- Market Risk Indicator (MRI): 0.80
- RSI: 74.02
- PPO: 0.89
- Hybrid Signal: Buy (Cash 0%)
- Recent relative divergence change: 4.70 (+)
- 7-day Rank change: 19 (+)
- 7-day Dynamic Expected Return change: -72.90 (-)
- Expected Return: 214.80%

**News & Significant Events**
- [2026-01-06] Novo Nordisk: NVO Stock To $100? - Forbes
- [2026-01-20] Lobbying Update: $2,120,000 of NOVO NORDISK INC. lobbying was just disclosed - Quiver Quantitative
- [2026-01-06] Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
- [2026-01-20] NVO Stock Today: January 20 Tariff Jitters Test Novo Nordisk Rally - Meyka
- [2026-01-20] ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO) - TipRanks
- [2026-01-16] NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? - Stocktwits

**Analyst Opinions**
- Analyst Consensus: Buy
- Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 56.36 / 73.95 / 41.94

**Comprehensive Analysis**
- Novo Nordisk's cumulative return is -40.00% lower than the S&P 500.
- Market Risk Indicator (MRI): 0.80.
- Recent stock price fluctuations suggest a possible correction or consolidation.
- Analyst consensus is Buy with a target price of $56.36.
- The stock has faced various significant events and news, including potential growth and hidden risks.
- Considering all factors, it is essential to carefully weigh the potential benefits and risks before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.